NCT03694444View on ClinicalTrials.gov

A Study of the C3 Complement Inhibitor AMY-101 in Adults With Gingivitis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

July 22, 2019

Primary Completion Date

August 30, 2020

Study Completion Date

October 30, 2020

Conditions
Gingivitis
Interventions
DRUG

AMY-101

C3 complement inhibitor

OTHER

Water for injection

Placebo

Trial Locations (1)

02142

Forsyth Institute, Cambridge

Sponsors
All Listed Sponsors
lead

Amyndas Pharmaceuticals S.A.

INDUSTRY

NCT03694444 - A Study of the C3 Complement Inhibitor AMY-101 in Adults With Gingivitis | Biotech Hunter | Biotech Hunter